# A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma

> **NCT02584920** · PHASE1,PHASE2 · COMPLETED · sponsor: **Shanghai Henlius Biotech** · enrollment: 87 (actual)

## Conditions studied

- B-cell Non Hodgkin's Lymphoma

## Interventions

- **DRUG:** HLX01
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT02584920
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2022-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02584920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02584920, "A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT02584920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*